Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. PFE, lowering the price target to $36 from $42. While PFE provided…

Related Keywords

Robyn Karnauskas ,Seagen Inc ,Pfizer Inc ,Truist Securities ,News ,Ggregator ,Reaking News ,Uration ,Media ,